Evaluation of an Ayurvedic intervention in improving the Quality of Life (QoL) in patients with metastatic (Stage 4) Non-Small Cell Lung Cancer (NSCLC) having negative epidermal growth factor receptor (EGFR) mutation -A Quasi experimental Pre-post design.

Ministry of Ayush0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1.Patients who are ready to provide written informed consent and willingness and ability to comply with study protocol.
•2.Newly diagnosed patients of metastatic (Stage 4) Non-Small Cell Lung Cancer (NSCLC)with histological confirmation, as per tissue biopsy.
•3.Age group 18 â?? 65 yrs irrespective of sex and religion.
•4.Epidermal growth factor receptor (EGFR)mutation negative, on EGFR mutation analysis
•5.Patients with PD-L1expression level <50%
•6.PatientshavinganEasternCooperativeOncologyGroup(ECOG) performance score not higher than 2.

•1.Patients with primary immunodeficiency and/or other causes of immunosuppression, including HIV or AIDS, autoimmune diseases, and other immunosuppressive disorders
•2.Patients with known or active HIV or AIDS
•3.Patients with known allergies or sensitivity to the study drug or components
•4.Patients with current cardiovascular disease and/or risk factors, such as angina pectoris, uncontrolled hypertension, myocardial infarction, congestive heart failure, stroke, or cardiac arrhythmia or having a history of the same in past 6 months.
•5.Patients with poorly controlled Hypertension ( >160/100 mm of Hg)
•6.Pregnant or nursing women
•7.Patients with other current malignancy
•8.Patients with current or history of drug or substance abuse
•9.Patients with psychiatric or mental illness
•10.Any medical conditions that, in the opinion of the investigator would interfere with the outcome of the study.
•11.Patients participating in any other interventional clinical trial.

发起方